



Molecular and Cellular Mechanisms of Pancreatitis

Guest Editor:

Dr. Gi-Sang Bae

Department of Pharmacology,
School of Korean Medicine,
Wonkwang University, Iksan
54538, Republic of Korea

Deadline for manuscript
submissions:

closed (30 September 2023)

Message from the Guest Editor

Dear Colleagues,

This Special Issue aims to discover and develop novel strategies or mechanisms, single compounds, natural products, or combination formulas with beneficial properties in various pancreatitis experimental models. Original research articles and reviews focused on molecular and cellular mechanisms are welcome. Topics of interest also include pharmacokinetics, metabolism, pharmacology, and toxicology related to the use of drugs in pancreatitis. While the focus of experimental drug mechanisms is primarily on the pharmacological research of new agents, novel pharmacodynamic and pharmacokinetic mechanisms that may explain or predict molecular and cellular mechanisms of acute and chronic pancreatitis already in use and/or provide potential targets for drug development are also welcome.

Dr. Gi-Sang Bae

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI